<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02279394</url>
  </required_header>
  <id_info>
    <org_study_id>14-338</org_study_id>
    <nct_id>NCT02279394</nct_id>
  </id_info>
  <brief_title>E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma</brief_title>
  <official_title>E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Blood Cancer Research Partnership</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Multiple Myeloma Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Leukemia and Lymphoma Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is aimed to determine the proportion of high risk smoldering multiple&#xD;
      myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide&#xD;
      and dexamethasone combination therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This research study is a Phase II clinical trial, which tests the effectiveness of the&#xD;
      investigational drugs elotuzumab, lenalidomide and dexamethasone in smoldering multiple&#xD;
      myeloma. Recent research studies have shown that early treatment of smoldering multiple&#xD;
      myeloma may delay or prevent the progression to active multiple myeloma. The purpose of this&#xD;
      research study is to learn whether the combination of elotuzumab, lenalidomide and&#xD;
      dexamethasone works in treating smoldering multiple myeloma.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 11, 2014</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Actual">September 3, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who are progression free at 2 years</measure>
    <time_frame>2 Years</time_frame>
    <description>Time from protocol therapy initiation to progression to symptomatic myeloma</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 Years</time_frame>
    <description>Response rate based on the IMWG criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of the combination therapy</measure>
    <time_frame>4 years</time_frame>
    <description>safety of the combination of Elotuzumab, lenalidomide+/- dexamethasone</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>4 years</time_frame>
    <description>Time from initiation of therapy to progression defined by the IMWG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 Years</time_frame>
    <description>Time from initiation of therapy to death</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Smoldering Myeloma</condition>
  <condition>Smoldering Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Elo / Len / Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 &amp; 15 Cycles 3-8&#xD;
Other Name: HuLuc63&#xD;
•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24&#xD;
Other Name: REVLIMID&#xD;
•Drug: Dexamethasone 40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8&#xD;
Other Name: Decadron</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elo / Len</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>•Drug: Elotuzumab 10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 &amp; 15 Cycles 3-8&#xD;
Other Name: HuLuc63&#xD;
•Drug: Lenalidomide 25 mg Oral; Days 1-21 days Cycles 1-24&#xD;
Other Name: REVLIMID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elotuzumab</intervention_name>
    <description>10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 &amp; 15 Cycles 3-8</description>
    <arm_group_label>Elo / Len</arm_group_label>
    <arm_group_label>Elo / Len / Dex</arm_group_label>
    <other_name>HuLuc63</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>25 mg Oral; Days 1-21 days Cycles 1-24</description>
    <arm_group_label>Elo / Len</arm_group_label>
    <arm_group_label>Elo / Len / Dex</arm_group_label>
    <other_name>REVLIMID</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8</description>
    <arm_group_label>Elo / Len / Dex</arm_group_label>
    <other_name>Decadron</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  Must have smoldering myeloma with high risk markers based on the Mayo OR the Spanish&#xD;
             criteria as described below&#xD;
&#xD;
          -  &gt;10% plasma cells in the bone marrow and any one or more of the following:&#xD;
&#xD;
               -  Serum M protein of 3 g/dL or greater&#xD;
&#xD;
               -  IgA SMM&#xD;
&#xD;
               -  Immunoparesis with reduction of two uninvolved immunoglobulin isotypes&#xD;
&#xD;
               -  Serum involved/uninvolved free light chain ratio ≥8 (but less than 100)&#xD;
&#xD;
               -  Progressive increase in M protein level (Evolving type of SMM)†&#xD;
&#xD;
               -  Bone marrow clonal plasma cells 50-60%&#xD;
&#xD;
               -  Abnormal plasma cell immunophenotype (≥95% of bone marrow plasma cells are&#xD;
                  clonal) and reduction of one or more uninvolved immunoglobulin isotypes&#xD;
&#xD;
               -  t (4;14) or del 17p or 1q gain&#xD;
&#xD;
               -  Increased circulating plasma cells&#xD;
&#xD;
               -  MRI with diffuse abnormalities or 1 focal lesion&#xD;
&#xD;
               -  PET-CT with focal lesion with increased uptake without underlying osteolytic bone&#xD;
                  destruction † Increase in serum monoclonal protein by ≥25% on two successive&#xD;
                  evaluations within a 6 month period&#xD;
&#xD;
          -  No evidence of CRAB (see below for details) criteria or new criteria of active&#xD;
             multiple myeloma which including the following:&#xD;
&#xD;
               -  Increased calcium levels (corrected serum calcium &gt;0.25 mmol/dL above the upper&#xD;
                  limit of normal or &gt;.275 mmol/dL)&#xD;
&#xD;
               -  Renal insufficiency (attributable to myeloma)&#xD;
&#xD;
               -  Anemia (Hb 2g/dL below the lower limit of normal or &lt;10g/dL)&#xD;
&#xD;
               -  Bone lesions (lytic lesions or generalized osteoporosis with compression&#xD;
                  fractures)&#xD;
&#xD;
               -  No evidence of the following new criteria for active MM including the following:&#xD;
                  Bone marrow plasma cells ≥ 60%, Serum involved/uninvolved FLC ratio ≥100, and MRI&#xD;
                  with more than one focal lesion&#xD;
&#xD;
                    -  Participants with CRAB criteria that are attributable to conditions other&#xD;
                       than the disease under study may be eligible&#xD;
&#xD;
          -  ECOG Performance Status (PS) 0, 1, or 2 (Appendix A)&#xD;
&#xD;
          -  The following laboratory values obtained ≤ 14 days prior to registration:&#xD;
&#xD;
               -  ANC ≥1000/µL&#xD;
&#xD;
               -  PLT ≥ 50,000/µL&#xD;
&#xD;
               -  Total bilirubin ≤ 2.0 mg/dL (If total is elevated check direct and if normal&#xD;
                  patient is eligible.)&#xD;
&#xD;
               -  AST ≤ 3 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  ALT ≤ 3 x institutional upper limit of normal (ULN)&#xD;
&#xD;
               -  Estimated creatinine clearance ≥ 60mL/min or a creatinine ≤ 2.2 mg/dL&#xD;
&#xD;
          -  Voluntary written informed consent before performance of any study-related procedure&#xD;
             not part of normal medical care, with the understanding that consent may be withdrawn&#xD;
             by the subject at any time without prejudice to future medical care&#xD;
&#xD;
          -  Females of childbearing potential* must have a negative serum or urine pregnancy test&#xD;
&#xD;
          -  Men must agree to use a latex condom during sexual contact with a female of&#xD;
             childbearing potential even if they have had a successful vasectomy&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent.&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
          -  Symptomatic Multiple Myeloma or any evidence of CRAB criteria including the new&#xD;
             criteria for overt myeloma. Any prior therapy for active Myeloma should also be&#xD;
             excluded. Prior therapy for smoldering myeloma is not an exclusion criteria.&#xD;
             Bisphosphonates are not excluded&#xD;
&#xD;
          -  Other concurrent chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy&#xD;
             considered investigational. Prior therapy with bisphosphonate is allowed. Prior&#xD;
             radiation therapy to a solitary plasmacytoma is allowed. Prior clinical trials for&#xD;
             smoldering MM or MGUS are allowed as long as the last therapy was at least 2 months&#xD;
             prior and there was no improvement in M spike&#xD;
&#xD;
          -  Serious medical or psychiatric illness likely to interfere with participation in this&#xD;
             clinical study&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 2 years of enrollment, with the&#xD;
             exception of complete resection of basal cell carcinoma or squamous cell carcinoma of&#xD;
             the skin, an in situ malignancy, or low-risk prostate cancer after curative therapy&#xD;
&#xD;
          -  Uncontrolled intercurrent illness&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to elotuzumab or lenalidomide&#xD;
&#xD;
          -  Known seropositive for or active viral infection with human immunodeficiency virus,&#xD;
             hepatitis B virus or hepatitis C virus. Patients who are seropositive because of&#xD;
             hepatitis B virus vaccine are eligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irene Ghobrial, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Francis Hospital and Medical Center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Maine Medical Center</name>
      <address>
        <city>Brewer</city>
        <state>Maine</state>
        <zip>04412</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 26, 2014</study_first_submitted>
  <study_first_submitted_qc>October 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 31, 2014</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Irene Ghobrial, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Smoldering myeloma</keyword>
  <keyword>Smoldering Multiple Myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Smoldering Multiple Myeloma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Elotuzumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

